Trefoil Therapeutics
Dr. Middaugh’s research is focused on understanding the changes in physicochemical properties that accompany the loss of biological activity of biopharmaceuticals and vaccines, and on developing new analytical techniques to monitor these changes at the molecular level. A detailed understanding of the causes and molecular mechanisms of instability will guide the design of more potent and stable biopharmaceutical and vaccine dosage forms. He holds a B.S. degree from the University of California, Santa Cruz, and a Ph.D. from Cornell. He completed a post-doctoral fellowship at the University of Minnesota.
This person is not in the org chart
This person is not in any offices
Trefoil Therapeutics
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.